Leukemia, Myelodysplasia, Transplantation

Conference Coverage

Acalabrutinib extends PFS in advanced CLL

AMSTERDAM – Monotherapy with the Bruton tyrosine kinase inhibitor acalabrutinib offered better progression-free survival, compared with rituximab-...

Conference Coverage

Ibrutinib tops chlorambucil against CLL

AMSTERDAM – The Bruton’s tyrosine kinase inhibitor was associated with a halving of risk for death, compared with chlorambucil.

How I will treat my next patient

Predicting outcomes in acute leukemia, NSCLC

Dr. Alan Lyss examines the latest research on predicting VTE risk in patients with acute leukemia and new data on the impact of steroids in non–...